National Cancer Institute (NCI): all 3,554 studies

Page 29 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Cilengitide in Treating Patients With Unresectable or Metastatic MelanomaTerminatedNCT00082875Phase 2
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• Magnetic Resonance Imaging to Locate and Characterize Prostate CancerCompletedNCT00082147Not applicable
• Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid TumorsCompletedNCT00081848Phase 1
• Early Detection of Barrett's EsophagusCompletedNCT00081354
• 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00081276Phase 2
• Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00081211Phase 1
• Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid TumorsCompletedNCT00080990Phase 1
• S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00080847Phase 2
• Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaCompletedNCT00080353Phase 2
• Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast CancerCompletedNCT00079625Phase 1
• Temsirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00079456Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00079430Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT00079404Phase 1
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00079352Phase 1
• CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung CancerCompletedNCT00079235Phase 2
• Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00079170Not applicable
• Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00079144Phase 2
• Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedNCT00079131Phase 2
• 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid TumorsCompletedNCT00079014Phase 1
• GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00078962Phase 1
• Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate CancerCompletedNCT00078910Phase 2
• 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal JunctionCompletedNCT00077545Phase 2
• Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
• Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077441Phase 2
• Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
• Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerCompletedNCT00077363Phase 2
• A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung CancerCompletedNCT00077350Phase 2
• Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal CancerCompletedNCT00077298Phase 2
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00077194Phase 2
• 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
• Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
• Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic LeukemiaCompletedNCT00076180Phase 1
• Alanosine in Treating Patients With Progressive or Recurrent Malignant GliomasCompletedNCT00075894Phase 1
• Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00075751Phase 2
• CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00075647Phase 2
• Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or NeuroblastomaCompletedNCT00075634Phase 1
• Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma MultiformeTerminatedNCT00075491Phase 2
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
• Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid TumorsCompletedNCT00074321Phase 1
• CC-8490 in Treating Patients With Recurrent or Refractory High-Grade GliomasCompletedNCT00074243Phase 1
• GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid TumorsCompletedNCT00074022Phase 1/2
• Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid TumorsCompletedNCT00072436Phase 1
• Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to MelanomaCompletedNCT00072163Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing CystectomyTerminatedNCT00072137Phase 1
• Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
• Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 GeneCompletedNCT00072111Phase 1
• Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic MelanomaCompletedNCT00072085Phase 2
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00071994Phase 2
• Vaccine Therapy in Treating Patients With Metastatic Breast CancerTerminatedNCT00071942Phase 1
• GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00070551Phase 1
• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaCompletedNCT00070525Phase 2
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00070447Phase 2
• Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal CancerTerminatedNCT00070265Phase 2
• Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast CancerCompletedNCT00070252Phase 1/2
• Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic MalignanciesTerminatedNCT00070239Phase 1
• Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal CancerTerminatedNCT00070122Phase 3
• Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast CancerCompletedNCT00070057Phase 1
• S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced MalignanciesCompletedNCT00068484Phase 1
• Anidulafungin in Treating Immunocompromised Children With NeutropeniaCompletedNCT00068471Phase 1/2
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor ActivityCompletedNCT00067821
• Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard ChemotherapyCompletedNCT00066846Phase 2
• Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung CancerCompletedNCT00066768Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• FR901228 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00066638Phase 2
• Oxaliplatin and Bortezomib in Treating Patients With Advanced CancerTerminatedNCT00066625Phase 1
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Radiation Therapy and the Natural History of Childhood CancersCompletedNCT00064883
• Perifosine in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00064324Phase 2
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderCompletedNCT00064246Phase 1/2
• Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00064142Phase 2
• Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
• Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedNCT00064103Phase 1/2
• Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
• Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerCompletedNCT00063947Phase 1
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular MelanomaCompletedNCT00062933Phase 2
• Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck CancerTerminatedNCT00062387Phase 2
• Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's MacroglobulinemiaCompletedNCT00062244Phase 1/2
• Irinotecan and Thalidomide in Treating Patients With Advanced Solid TumorsCompletedNCT00062127Phase 1
• Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung CancerCompletedNCT00062101Phase 2
• Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
• Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal JunctionTerminatedNCT00061958Phase 2
• Using Fiducial Markers to Aid in Prostate Cancer Radiation TreatmentCompletedNCT00061347Phase 1
• Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate CancerCompletedNCT00060437Phase 2
• A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerCompletedNCT00060411Phase 1
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerCompletedNCT00060307Phase 2
• Tipifarnib in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00060125Phase 2
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell TransplantationCompletedNCT00060021Not applicable
• Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal InfectionsCompletedNCT00059878Phase 2

← National Cancer Institute (NCI) overview and focus areas